CO2024007413A2 - Conjugados peptídicos de inhibidores de tubulina peptídica como agentes terapéuticos - Google Patents
Conjugados peptídicos de inhibidores de tubulina peptídica como agentes terapéuticosInfo
- Publication number
- CO2024007413A2 CO2024007413A2 CONC2024/0007413A CO2024007413A CO2024007413A2 CO 2024007413 A2 CO2024007413 A2 CO 2024007413A2 CO 2024007413 A CO2024007413 A CO 2024007413A CO 2024007413 A2 CO2024007413 A2 CO 2024007413A2
- Authority
- CO
- Colombia
- Prior art keywords
- peptide
- therapeutic agents
- tubulin inhibitors
- conjugates
- peptide conjugates
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/655—Somatostatins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163280409P | 2021-11-17 | 2021-11-17 | |
| PCT/US2022/079973 WO2023091957A1 (en) | 2021-11-17 | 2022-11-16 | Peptide conjugates of peptidic tubulin inhibitors as therapeutics |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2024007413A2 true CO2024007413A2 (es) | 2024-11-18 |
Family
ID=84799580
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2024/0007413A CO2024007413A2 (es) | 2021-11-17 | 2024-06-13 | Conjugados peptídicos de inhibidores de tubulina peptídica como agentes terapéuticos |
Country Status (14)
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2022000449A (es) | 2019-07-10 | 2022-04-25 | Cybrexa 2 Inc | Conjugados peptídicos de citotoxinas como terapéuticos. |
| BR112022000297A2 (pt) | 2019-07-10 | 2022-03-15 | Cybrexa 3 Inc | Conjugados de peptídeos de agentes de alvo de microtúbulos como terapêuticos |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006078816A2 (en) * | 2005-01-18 | 2006-07-27 | The Board Of Governors For Higher Education | Selective delivery of molecules into cells or marking of cells in diseased tissue regions using environmentally senstive transmembrane peptide |
| EP2927227A4 (en) * | 2013-01-03 | 2015-12-30 | Celltrion Inc | ANTIBODY CONCENTRATOR REMEDY CONJUGATE, METHOD OF MANUFACTURING THEREOF, AND ANTIBODY TOGETHER THEREWITH |
| WO2018023098A1 (en) * | 2016-07-29 | 2018-02-01 | Memorial Sloan Kettering Cancer Center | Radiolabeled ligands for targeted pet/spect imaging and methods of their use |
| MX2022000449A (es) * | 2019-07-10 | 2022-04-25 | Cybrexa 2 Inc | Conjugados peptídicos de citotoxinas como terapéuticos. |
| BR112022000297A2 (pt) * | 2019-07-10 | 2022-03-15 | Cybrexa 3 Inc | Conjugados de peptídeos de agentes de alvo de microtúbulos como terapêuticos |
-
2022
- 2022-11-16 AU AU2022390891A patent/AU2022390891A1/en active Pending
- 2022-11-16 EP EP22836006.1A patent/EP4433095A1/en active Pending
- 2022-11-16 CN CN202280089024.1A patent/CN118574642A/zh active Pending
- 2022-11-16 US US18/056,117 patent/US20230416331A1/en active Pending
- 2022-11-16 MX MX2024005938A patent/MX2024005938A/es unknown
- 2022-11-16 CA CA3243300A patent/CA3243300A1/en active Pending
- 2022-11-16 WO PCT/US2022/079973 patent/WO2023091957A1/en not_active Ceased
- 2022-11-16 JP JP2024529599A patent/JP2024542212A/ja active Pending
- 2022-11-16 TW TW111143837A patent/TW202330015A/zh unknown
- 2022-11-16 IL IL312884A patent/IL312884A/en unknown
- 2022-11-16 PE PE2024001102A patent/PE20242180A1/es unknown
- 2022-11-16 KR KR1020247020055A patent/KR20240130157A/ko active Pending
-
2024
- 2024-05-16 CL CL2024001486A patent/CL2024001486A1/es unknown
- 2024-06-13 CO CONC2024/0007413A patent/CO2024007413A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4433095A1 (en) | 2024-09-25 |
| CL2024001486A1 (es) | 2024-11-29 |
| PE20242180A1 (es) | 2024-11-07 |
| AU2022390891A1 (en) | 2024-06-06 |
| IL312884A (en) | 2024-07-01 |
| CA3243300A1 (en) | 2023-05-25 |
| MX2024005938A (es) | 2024-08-14 |
| KR20240130157A (ko) | 2024-08-28 |
| TW202330015A (zh) | 2023-08-01 |
| JP2024542212A (ja) | 2024-11-13 |
| WO2023091957A1 (en) | 2023-05-25 |
| CN118574642A (zh) | 2024-08-30 |
| US20230416331A1 (en) | 2023-12-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2022001316A2 (es) | Conjugados peptídicos de citotoxinas como terapéuticos | |
| CL2020002719A1 (es) | Moduladores de nlrp3 | |
| CO2023018231A2 (es) | Restos de administración terapéutica novedosos y usos de estos | |
| CL2019000221A1 (es) | Compuestos de tiazolo-piridina sustituida como inhibidores de malt1. | |
| BR112021024236A2 (pt) | Proteínas multiespecíficas | |
| MX2019009653A (es) | Inhibidores de mnk sustituidos con piperidina y metodos relacionados con los mismos. | |
| CR20230146A (es) | Moléculas de unión a b7-h4 terapéuticas | |
| CL2024001486A1 (es) | Conjugados peptidicos de inhibidores peptidicos de tubulina como terapeuticos. | |
| ECSP22010121A (es) | Conjugados peptídicos de agentes dirigidos a microtúbulos como terapéuticos | |
| CR20180222A (es) | Agentes inductores de apoptosis para el tratamiento del cáncer y de enfermedades inmunes y autoinmunes (divisional 2012-648) | |
| ECSP20061378A (es) | COMPUESTOS DIÓLICOS DE AMINOPIRAZINA COMO INHIBIDORES DE PI3K-gamma | |
| CL2020000085A1 (es) | Moduladores de nlrp3. | |
| MX2017012102A (es) | Agentes citotoxicos bifuncionales que contienen el farmacoforo de cti. | |
| BR112022009672A2 (pt) | Tratamento de cânceres com conjugados anticorpo-fármaco (adc) que se ligam a proteínas 191p4d12 | |
| NI201801172A (es) | Nuevos compuestos para el tratamiento de enfermedades parasitarias | |
| CL2023003187A1 (es) | Regímenes de dosificación de conjugados peptídicos de inhibidores de la topoisomerasa i. | |
| CO2025016647A2 (es) | Inhibidores de egfr para el tratamiento de enfermedades | |
| CO2019001967A2 (es) | Compuestos de tiazolo-piridina sustituida como inhibidores de malt1 | |
| DOP2025000274A (es) | Inhibidores de egfr para el tratamiento de enfermedades | |
| MX2025001061A (es) | Degradación de proteínas dirigida de parp14 para usar en terapia. | |
| AR133538A1 (es) | Péptidos cíclicos dirigidos a fap y conjugados de los mismos |